Replimune Group, Inc.
- REPL
- NASDAQ
- Biotechnology
- Oncolytic Immunotherapy
- Cancer Gene Therapy
$11.05
Today +1.75%Quote Oct 19, 2026, 08:00 PM UTC
−15.46%over the last month
Max drawdown −19.4%From 1-month high −18.0%3 months +0.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Replimune
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
465
Market value
$927.6M
Quote Oct 19
Floor
$9.84
10.9% below price
Resistance
$11.74
6.3% above price
Price vs analyst targets
15 analysts
Lowest target
$17.00Highest target
$20.00
$17.00Highest target
$20.00
- Price $11.05
- Average target $18.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 69% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about REPLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free